Our website uses cookies to bring you an easy and personalised browsing experience. By continuing, you consent to our cookie policy on this device. For More info, please see our Privacy Statement

ICECaP Publications

ICECaP Adjuvant

  • ICECaP Working Group. (2015) ‘The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)’ Journal of the National Cancer Institute 107:12
  • Xie, W, Regan, MM, Buyse, M, Halabi, S, Kantoff, PW, Sartor, O, Soule, H, Clarke, NW, Collette, L, Dignam, JJ, Fizazi, K, Paruleker, WR, Sandler, HM, Sydes, MR, Tombal, B, Williams, SG, Sweeney, CJ and on behalf of the ICECaP Working Group (2017) ‘Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer’ Journal of Clinical Oncology 35:27, 3097-3104
    DOI: 10.1200/JCO.2017.73.9987
  • Sweeney, C. (2018) ‘Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?’ European Urology 74:4, 420-421
    DOI: 10.1016/j.eururo.2018.06.036
  • Xie, W, Halabi, S, Tierney, JF, Sydes, MR, Collette, L, Dignam, JJ, Buyse, M, Sweeney, CJ, Regan, MM (2019) ‘A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses’ JNCI Cancer Spectrum 3:1 pkz002
    DOI: 10.1093/jncics/pkz002
  • Xie, W, Regan, MM, Buyse, M, Halabi, S, Kantoff, PW, Sartor, O, Soule, H, Berry, D, Clarke, N, Collette, L, De Abreu Lourenco, R, Dignam, M, Eisenberger, M, James, N, Fizazi, K, Gillessen, S, Loriot, Y, Mottet, N, Parulekar, W, Sandler, H, Spratt, D, Sydes, M, Tombal, B, Williams, S & Sweeney, CJ and on behalf of the ICECaP Working Group (2020) ‘Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation’ Journal of Clinical Oncology 38:26, 3032-3041
    DOI: 10.1200/JCO.19.03114
  • Marc Buyse, Everardo D Saad, Tomasz Burzykowski, Meredith M Regan, Christopher S Sweeney, Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy, The Oncologist, Volume 27, Issue 4, April 2022, Pages 266–271, DOI: 10.1093/oncolo/oyac006


  • Vale, CL, Burdett, S, Rydzewska, LH, Albiges, L, Clarke, NW, Fisher, D, Fizazi, K, Gravis, G, James, ND, Mason, MD, Parmar, MK, Sweeney, C.J, Sydes, MR, Tombal, B, Tierney, JF, the STOpCaP Steering Group (2016). Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncology 17: 2, 243-256
    DOI: 10.1016/S1470-2045(15)00489-1
  • Rydzewska, LHM, Burdett, S, Vale, CL, Clarke, NW, Fizazi, K, Kheoh, T, Mason, MD, Miladinovic, B, James, ND, Parmar, MKB, Spears, MR, Sweeney, CJ, Sydes, MR, Tran, N, Tierney, JF, the STOPCaP Abiraterone Collaborators (2017). Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. European Journal of Cancer 84: 88-101
    DOI: 10.1016/j.ejca.2017.07.003
  • Vale, CL, Fisher, DJ, White, IR, Carpenter, J, Burdett, S, Clarke, NW, Fizazi,, K, Gravis, G, James, ND, Mason, MD, Parmar, MKB, Rydzewska, LH, Sweeney, C.J, Spears, MR, Sydes, MR, Tierney, JF (2018). What is the optimal systemic treatment for men with metastatic, hormone- naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology 29: 5, 1249-1257
    DOI: 10.1093/annonc/mdy071
  • Tierney, JF, Vale, CL, Parelukar, WR, Rydzewska, L, Halabi, S (2019) Evidence synthesis to accelerate and improve the evaluation of therapies for metastatic hormone-sensitive prostate cancer. European Urology Focus 5: 2, 137-143.
    DOI: 10.1016/j.euf.2019.01.005 (abstract only)
  • Burdett, S, Boeve, LM, Ingleby, FC, Fisher, DJ, Rydzewska, LH, Vale, CL, van Andel, G, Clarke, NW, Hulshof, M, James, ND, Parker, CC, Parmar, MK, Sweeney, CJ, Sydes, MR, Tombal, B, Verhagen, PCMS, Tierney, JF, the STOPCAP M1 Radiotherapy Collaborators (2019). Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. European Urology 76: 1,115-124
    DOI: 10.1016/j.eururo.2019.02.003